1. Introduction

Meningiomas arise from the meningeal coverings of the central nervous system. With an annual incidence of around 5 per 100,000 individuals, they are the most frequent primary tumors in the central nervous system (30%) [1,2]. Meningiomas are diagnosed because of neurological symptoms (neurological deficits, epilepsy, elevated intracranial pressure) or can be discovered on brain imaging for unspecific unrelated symptoms, for instance tinnitus or headaches. Magnetic resonance imaging (MRI) are often sufficient to make the diagnosis and allow precise location and measurement of the tumor. The frequency of meningiomas is probably underestimated, since systematic screening MRI showed that the prevalence of undiagnosed meningiomas is 0.5% in the subjects aged 45–59 years and 1.6% after 75 years [3].

Meningiomas are more commonly reported in females (sex ratio 2–4:1) [4] and the incidence increases with age. The only proved extrinsic risk factors are radiation therapy and hormone intake, both with a dose–response relationship. Meningiomas can arise in all irradiated patients, even after low-dose ionizing radiation like for tinea capitis treatment, but the risk is higher in patients exposed to high-dose radiotherapy: in children exposed to cranial radiotherapy, the incidence of meningioma is 5.6% by age 40 [5,6]. Hormones such as cyproterone acetate, a synthetic steroidal antiandrogen, increase the risk of developing and growing meningiomas up to 11 times [7–9]. Other suspected risk factors, like cell phone exposure, are not confirmed in large cohorts [10].

2. Classification and prognosis

2.1. Meningioma grading

Meningiomas are classified according to the 2000/2007/2016 WHO classifications based on their histological appearance, divided into 15 subtypes, and on various aggressiveness criteria (mitoses, necrosis, cellular aspect), that are detailed in Table 1 [11]. Overall, more than 80% are grade I benign tumors, while atypical grade II include 4–15% of meningiomas and malignant grade III account for 1–3% of cases [12]. In the 2004–2010 US cohort of primary brain tumors, the proportion of each grade was 94.6, 4.2, and 1.2%, respectively [13].

Grades II and III meningiomas are diagnosed in younger patients (median age 57 year old) and are more common in male [14,15] and can develop de novo or arise from low-grade meningiomas transformation; those tumors seem to constitute two different molecular subtypes, de novo meningiomas conferring a better survival [16].

Although histological grading is the current gold standard in terms of diagnosing and treating meningiomas, its relevance is a subject of debate. Tumors are very heterogeneous within each grade, especially when grading relies on minor criteria, brain invasion or histologic aspect rather that mitotic count [17]. Moreover, some diagnostic criteria are vaguely defined and subject to a high interobserver bias [18–20]. In prospective clinical trials, when studying pathology concordance levels for meningioma classification and grading, there are respective concordance rates of 93.0, 87.8, and 93.6% for grades I–II–III, which is higher than those found in glioma pathology (maximum 74%), but is still considered suboptimal;
the authors suggest that education and clarification of subjective criteria, alongside biomarkers, will improve reproducibility [21]. Many discrepancies also arise from the evolution of histological classifications, that led to a dramatic increase of the proportion of grade II tumors, from 4.4% before 2000 up to 32.7% in 2006 [22,23]. In France, 13,038 meningiomas were histologically diagnosed between 2006 and 2010, among which 8.5% of atypical meningiomas but this number varies from 5 to 23% in other series and significantly increased after 2007 [2,24]. This has a considerable impact on therapeutic choices and clinical results and should be taken into account in retrospective series of patients, with particular attention paid to centralized histological review according to the 2016 WHO classification.

### 2.2. Other classifications

Although histological grading remains the gold standard in terms of diagnosis and treatment options, it is relevant to classify meningiomas according to other factors, such as the influence of hormone intake or the tumor location, as it may affect the treatments feasibility, and because the distribution of grading varies in these groups. Topographic description includes supra- or infra-tentorial or anterior, middle, and posterior fossa tumors, midline or lateral lesions, and invasion of other structures such as vessels or cranial nerves (cf. Figure 1). Meningiomas located in the anterior fossa, median middle fossa or anterior calvarium are more frequently grade I meningotheelial or transitional meningiomas, whereas secretory

<table>
<thead>
<tr>
<th>Grade 1 – Benign</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningothelial</td>
</tr>
<tr>
<td>Fibrous (fibroblastic)</td>
</tr>
<tr>
<td>Transitional (mixed)</td>
</tr>
<tr>
<td>Psammomatous</td>
</tr>
<tr>
<td>Angiomatous</td>
</tr>
<tr>
<td>Microcystic</td>
</tr>
<tr>
<td>Secretory</td>
</tr>
<tr>
<td>Lymphocyte rich</td>
</tr>
<tr>
<td>Metaplastic</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade II – Atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear cell</td>
</tr>
<tr>
<td>Chordoid</td>
</tr>
<tr>
<td>Or 3 minor criteria:</td>
</tr>
<tr>
<td>– Increased cellularity</td>
</tr>
<tr>
<td>– Small cell with high N/C ratio</td>
</tr>
<tr>
<td>– Large and prominent nucleoli</td>
</tr>
<tr>
<td>– Patternless or sheet-like growth</td>
</tr>
<tr>
<td>– Foci of ‘spontaneous’ or geographic necrosis</td>
</tr>
<tr>
<td>Or brain invasion</td>
</tr>
<tr>
<td>Or ≥19 mitotic figures/10 HPF</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade III – Anaplastic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhabdoid</td>
</tr>
<tr>
<td>Papillary</td>
</tr>
<tr>
<td>Or ≥20 mitotic figures/10 HPF</td>
</tr>
<tr>
<td>Or frank sarcomatous carcinomatous histology</td>
</tr>
</tbody>
</table>

---

**Table 1.** Current histological criteria for grading meningiomas according to the 2016 WHO classification.

---

**Figure 1.** MRI of grade I meningiomas, T1-weighted gadolinium enhanced sequences. (a) This meningioma developing on the right frontal convexity can be treated surgically. (b) This right temporal base meningioma should be treated surgically because of its volume and accessibility. Total resection may not be possible because of the proximity of the middle cerebral artery. Radiotherapy or radiosurgery will be indicated in case of secondary regrowth. (c, d) This extensive skull base meningioma encloses both internal carotids, middle cerebral arteries, cranial nerves including optic nerves, and the sella turcica. Resection surgery is not possible and only a biopsy should be considered. In this particular case, the patient benefited from drilling of hyperostic bone to release the optic nerves, and her ovarian stimulation was stopped. She received proton beam radiotherapy. Systemic therapy would bring a significant clinical benefit by sparing the functional structures in the area.
meningiomas more often develop in the lateral middle fossa, median posterior fossa as well as anterior fossa and median middle fossa [25,26]. Those subtypes are also associated with particular genetic profiles that are detailed below.

Recently, some authors have addressed the need for more reliable predictive markers by exploring the molecular profiles of meningiomas [27]. Recurrent mutations have been identified, but the main step toward a multilayered classification integrating clinical, histological, and biological data has been brought by an epigenetics study: Sahm et al. found that patients with meningioma could be divided into six DNA methylation groups, and that those groups were more accurately stratified for tumor behavior than the WHO classification [20].

2.3. Clinical prognostic factors

Even though meningiomas are benign tumors in most cases, patients have a shorter survival compared to a matched population. In 1998, the 5-year survival was 70% for the so-called benign meningiomas and 55% for malignant ones [28], which is shorter than age-matched populations [4,29]. Nowadays, the 5- and 10-year survival rates are 65 and 50% for grade II and III meningiomas [14,30]. Around 10% of grade I, 30–40% of grade II and 50–90% of grade III recur or progress after 10 years [4,18]. Prognostic factors include age, male gender, low Karnofsky performance status, high grade, high mitotic rate, subtotal surgical resection and involvement of the optic nerve [4,14,15,31,32]. Somatic metastases are exceptional (0.1%) [33] but isolated cases have been described for grade II and III recurrent meningiomas, in parasagittal locations that allow venous diffusion through the superior sagittal sinus [15,34]. Genetic and epigenetic subtypes seem to predict prognosis more accurately and are progressively becoming common practice for complex cases [20].

In brief, the most problematic meningiomas fall into two categories. First, those that develop on the skull base: although usually low grade, they enclose vasculo-nervous structures, posing a surgical challenge and causing functional and vital risks (cf. Figure 1). Second, grade II–III meningiomas, classically located at the skull convexity, that frequently recur, especially when venous invasion hinders complete surgical resection (cf. Figure 2).

3. First-line treatments

3.1. Observation and symptomatic treatments

The classical first-line treatment for all meningiomas is surgery. However, a wait-and-see strategy should always be considered when the clinical situation allows it, with regular clinical and MRI follow-up: predictive factors for observing rather than operating newly diagnosed meningiomas are a small diameter, below 2.5 cm, the absence of neurological symptoms, calcifications on brain CT-scan and hyposignal intensity on

![Figure 2. MRI of a patient with recurrent grade III meningioma, T1-weighted gadolinium enhanced sequences. (a) Initial presentation. The left occipital meningioma is amenable to surgical resection. (b) Postoperative MRI shows gross total resection of the tumor. (c) Despite repeated surgery and radiotherapy, the meningioma recurred locally recurrence with bone and skin invasion. (d) A few months later, MRI shows multinodular relapse with diffuse pachymeningeal thickening in both hemispheres. In those situations, global imaging follow-up is necessarily based on volumetric measures. This case underlines the need for systemic therapy in refractory patients.](image-url)
brain MRI [35]. Observation is classically not a long-term option for tumors ≥4 cm, and for those with an initial growth rate of ≥20%/year for tumors <2.5 cm and ≥1 cm³/year for tumors ≥2.5 cm [36].

Careful questioning of the patients must look for exogenous hormone use (cyproterone acetate), sometimes prescribed for treating hirsutism, acne, seborrhea, alopecia or in transsexual patients. In those situations, withdrawing the hormone treatment is sometimes sufficient to stabilize and even decrease the tumor size [37–39]: some authors reported up to 80% volume reduction after one year of hormone disruption [40]. For the same reasons, meningiomas can also spontaneously decrease after pregnancy [41].

Symptomatic treatments include oral or intravenous steroids, that may help improve the mass effect by reducing peripheral edema to temporarily relieve the symptoms, for instance before surgery. Antiepileptic drugs are introduced only in epileptic patients, but preventive treatment is not recommended. Surgical removal helps achieving seizure freedom in 70% of preoperatively epileptic patients, but it can also induce epilepsy, in 12% of the preoperatively non-epileptic patients [42].

### 3.2. Surgery

During the last decades, the surgical techniques have evolved progressively with more recently the development of minimally invasive endoscopic transphenoidal approaches for skull base meningiomas [43]. However, after being very popular, it is already declining because serious local and neurological complications may arise, with cerebrospinal fluid leakage [44].

Depending on the location of the tumor and of the invasion of surrounding structures and brain parenchyma, total removal is not always possible. Post-operative Simpson grading based on the surgeon opinion, evaluates removal from grade 1 (complete) to 5 (simple biopsy) and allows, to predict symptomatic recurrence at 10 years, from 10 to 100% [45], regardless of the histological grade. Several authors have questioned this result since it was first published in 1957, especially in the absence of systematic postoperative MRI. It has been confirmed that, for grade II meningiomas for instance, Simpson 1 resection patients have a longer overall and progression free survival [15]. For grade III meningiomas selectively, the progression-free survival at 5 years is 28% after gross total resection alone, versus 0% after subtotal removal alone [46,47]. Although the results all tend to favor gross total resection, this goal should not affect the patients’ immediate neurological status, and combined strategies could be used to maximize progression-free survival while reducing the neurological risks.

### 3.3. Radiation therapy as a first-line treatment

Although surgery remains central because it can relieve the tumor mass effect and establish histological diagnosis, radiation therapy has become a first-line option for some meningiomas, particularly skull base lesions encasing vasculo-nervous structures such as the optic nerve sheath or the cavernous sinus [48]. Radiation treatment alone may be offered if imaging is typical and surgery not feasible. Fractioned and hypofractioned stereotactic radiotherapy and radiosurgery, single or multiple doses, have all proved beneficial to patients with a high tumor control rate varying from 85 to 100% at 5 years [49,50]. Those results, alongside with radiation-induced toxicity, make these treatments particularly relevant for intractable tumors <3 cm. Side-effects of stereotactic radiotherapy for small tumors are mild [51,52], but cases of radionecrosis have been reported, and pituitary function must also be monitored after skull base irradiation [53].

#### 3.4. Adjuvant treatment – radiotherapy indications

Grade I meningiomas are usually treated by surgery or radiosurgery alone, and adjuvant radiotherapy is only necessary for growing remnants [54]. On the contrary, grade II and III meningiomas are aggressive tumors with higher recurrence rates, up to, respectively, 30–40% and 50–80% at 5 years, versus 10% for grade I [12,15,19,31,55]: adjuvant radiation therapy of the tumor zone might be beneficial even after gross total resection [15,19,56]. Recurrences can be local or affect all the meninges [57]. Several types of radiation therapy have been proposed and must be chosen depending of the grade, size and location of the tumor. In case of a limited tumor, radiosurgery or stereotactic radiotherapy in single or multiple doses is appropriate (Figure 3).

For recurrent, multiple or extensive lesions, external beam radiotherapy is the standard technique, with a dose of up to 70 Gy for grade II–III meningiomas, whether 3D conformal radiotherapy or intensity-modulated radiation therapy with or without tomotherapy [54]. Proton radiotherapy is also beneficial, and can be used in combination with photon radiotherapy [58].

For grade III tumors, it is established that adjuvant radiation improves long-term control and overall survival [15,19,46], even after total gross removal: the progression-free survival at 5 years is improved from 28% for total removal alone, versus 57% for total removal with adjuvant radiotherapy [46]. In contrast, there is conflicting evidence for its role in grade II meningiomas. It has been shown that radiation therapy improves overall and progression-free survival when the tumor has been sub-totally removed [59], but not after total gross resection [60]. Moreover, retrospective studies did not always find a beneficial effect, and no prospective trial has been published yet [15,30,51,61]. Indeed, reported side effects of radiotherapy and radiosurgery are usually mild but there is also evidence that radiation increases the risk of malignant transformation [62].

Three comparable prospective trials started in the past years: The European Organization for Research and Treatment of Cancer (EORTC) led a randomized phase II study in 2008–2013, evaluating adjuvant postoperative radiation therapy versus observation in patients with newly diagnosed grade II or grade III meningiomas (NCT00626730, Switzerland). This trial was interrupted because of major protocol deviations and lack of inclusions [63]. The second one is the American RTOG 0539 (NCT00895622) trial concerning observation for low-risk meningiomas and radiotherapy for intermediate and high-risk meningiomas, included 244 patients and is still ongoing. Initial outcomes after 3 years show that patients with completely resected grade II and recurrent grade I treated with postoperative radiotherapy experience a 96% rate of progression free survival [64]. Last, a phase II randomized controlled trial started in 2015 in the UK (ROAM/EORTC-1308) [65] comparing
radiation (60 Gy in 30 fractions) versus observation following surgical resection of atypical meningioma.

In clinical practice, therapeutic decision varies in different centers. In the UK, Germany, and France, 59, 74, and 80% of neurosurgeons, respectively, treat patients with radiotherapy after subtotal grade II removal, while 45–60% of neurosurgeons advise immediate adjuvant radiotherapy after grade II gross total resection [15,66,67]. These numbers have changed dramatically before and after 2000, reflecting the changes in grade II meningiomas aggressiveness [23].

### 3.5. Follow up

There is no solid data about the best follow-up schedule. The European Association of Neuro-Oncology offers recommendations based on expert consensus [18]. For newly diagnosed asymptomatic meningiomas, a first MRI with injection may be considered after 6 months, then annually unless symptoms appear. After surgery, MRI should be performed ideally <48 h to document the extent of resection. For completely resected grade I meningiomas, MRI controls can be performed annually for 5 years then every 2 years. After incomplete resection, a more vigilant follow up could include MRI at 6 and 12 months, then annually. For grade II and III tumors, it is appropriate to perform MRI every 6 months for 5 years, then annually, or even every 3 months in case of rapidly evolving lesions. In order to avoid underestimating slow tumor growth on MRI, some systematic rules should be followed: always compare the new MRI to a reference MRI obtained just after surgical resection, or when the meningioma was discovered; measure meningiomas with volumes rather than with planar dimensions [57].

### 4. Medical treatments for recurrent meningiomas

Long-term follow-up studies have shown that, even among the so-called completely resected tumors, up to 60% may recur after 15 years [19]. Usual treatments, as discussed nowadays by multidisciplinary teams, include repeating surgery and performing targeted radiosurgery in order to complete radiotherapy. Systemic therapies are chosen on an individual basis once surgical and radiation possibilities have been exhausted because of their limited efficacy. Classical chemotherapy schemes (temozolomide, irinotecan, doxorubicin, ifosfamide) have not proven efficient [68,69]. Hydroxyurea only has showed a stabilizing activity in some series [70–72], but this has not been consistently confirmed [73–75]. Some authors suggest that individual chemotherapy should be based on the expression of drug-resistant genes [69,76]. As a proof of concept, long-term efficacy of mitoxantrone and hydroxyurea has been reported in a specifically selected patient in whom mRNA analysis had predicted sensitivity to the chemotherapy [77]. The EORTC started a randomized trial in 2015 evaluating trabectedin, an alkylating agent classically used in soft-tissues sarcomas, in refractory recurrent grade II–grade III meningiomas (NCT02234050).

Hormonal treatments, either mifepristone or tamoxifen, have resulted in minor responses for some patients but without any impact on progression or survival [78]. Interferon-alpha helps stabilizing or diminishing recurrent meningiomas [79–82] and so do somatostatin analogs [68]. All these treatments have a limited and not highly repeatable effect. Combination of treatments may improve their efficacy, as tested in a currently recruiting prospective trial (NCT02333565, France) offering octreotide, a somatostatin analog, to enhance the inhibitory effect of everolimus, a mTOR inhibitor, in grade II–III and recurrent grade I meningiomas [83]. A phase II trial proposing a mTor
Antiangiogenic treatments are increasingly used in clinical practice. Some molecules targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, such as sunitinib and vatalanib, prolonged progression-free intervals in patients with recurrent grade II and III meningiomas [84,85]. In particular, sunitinib was beneficial in a prospective phase II trial [86], and bevacizumab prolonged progression-free survival in retrospective studies [87,88], independently of molecular mutations, including NF2 [89]. An ongoing clinical trial (NCT01125046, USA) prospectively evaluates the efficacy of bevacizumab in recurrent or progressive meningiomas, and should be completed by 2018. In both cases, intracranial hemorrhage was the main adverse effect, in up to 20% of patients.

Immunotherapy may offer new therapeutic options. High-grade meningiomas show PD-L1+ cells infiltration, which makes immune checkpoint inhibitors potentially beneficial treatments, like in mesotheliomas and pancreatic carcinomas [90]. Current clinical trials test anti-PD1 drugs pembrolizumab (NCT03279692) and nivolumab (NCT03173950) in recurrent or residual high-grade meningiomas.

5. Molecular characterization and implications
Molecular characterization of meningiomas has developed in the last decade and is already paving the way to new therapeutic approaches [91]. The most common genetic event is the inactivation of the NF2 tumor suppressor gene, found in 55% of all meningiomas [25], and in 100% in patients with Neurofibromatosis type 2 who develop multiple meningiomas in addition to bilateral vestibular schwannoma [92]. Recently, mutations in genes such as TRAF7, AKT1, KLF4, SMO, PIK3R1, TERT, ARID1A, PIK3CA were identified, accounting altogether with NF2 for 80% of meningiomas [25,93–95]. Animal models developed in vivo in mice and in vitro lead to a better understanding of the molecular mechanisms that initiate tumorigenesis (in particular, NF2 mutation) and explain malignant transformation (added CDKN2A alteration for instance) [96–99].

Molecular characterization is being increasingly used for developing and directly testing therapeutic hypothesis, as show the inclusion criteria of some of the 23 ongoing clinical trials for patients with meningiomas indexed on clinicaltrials.org. Some molecular findings are particularly relevant either because they correlate with specific locations of meningiomas and may be targeted in case of surgically intractable tumors, or because specific treatments already exist. For instance, because of SMO role in embryogenesis, SMO mutations have been identified mainly in skull base meningiomas [26,93], and TRAF7 mutations in aggressive midline meningiomas [100]. Analyzing the molecular profile of these meningiomas, either after surgical sampling or maybe, one day, based on their MRI aspect, could allow safer individual targeted treatments, such as SMO inhibitor sonidegib.

An ongoing phase II clinical trial (NCT02523014, USA) [95] offers a new approach, where therapies are administered based on precise molecular identification of target mutations; patients with progressive meningiomas harboring NF2 mutations receive a FAK inhibitor (classically used in mesotheliomas [101]), whereas those harboring SMO mutations receive vismodegib, which has proved beneficial in patients with PTCH1-SMO mutated medulloblastomas [102]. This basket trial opens the doors to treatments based on molecular profiling, rather than histology.

6. Expert commentary
Meningioma is the most frequent primary tumor in the central nervous system, the most frequent pathology treated by neurosurgeons for decades. If surgical resection remains the first-line treatment in symptomatic patients, radiation therapy may be a useful alternative or adjuvant treatment, either for difficult skull base cases or aggressive variants.

So far, the recently modified histological WHO classification serves as a basis for therapeutic decision: while grade I tumors seldom recur and can be simply monitored after surgery, patients with high-grade meningiomas should benefit from postoperative radiation therapy. Grade II meningiomas constitute a highly heterogeneous group of tumors, precluding straightforward therapeutic guidelines. Those guidelines are highly debated because of the weak reliability of histological criteria and finding molecular predictive factors is at the heart of current research.

Recurrent meningioma is a complex condition in which surgical and radiosurgical options are to be considered first. Pharmacological alternatives are very diverse but none of them has proved systematically beneficial. Many clinical trials, sometimes including molecular characterization of the tumor, are ongoing and should be proposed to patients with intractable tumors whenever possible.

7. Five-year view
Molecular characterization of meningiomas has led to a new definition of meningiomas, based not on their histological aspect but on molecular changes affecting most of the time NF2, but also AKT, SMO, TRAF7… Interestingly, these mutations seem to be associated with particular locations or aggressiveness subtypes, for instance SMO mutations are associated with olfactory groove recurrent meningiomas. Most of them can be targeted by molecules that have been developed in other clinical contexts, such as vismodegib for SMO-mutated lesions. In parallel, the epigenetic approach to meningiomas has recently led to a new classification based on methylation profiles that seems to predict very accurately tumor behavior. Although still beginning, those complementary perspectives pave the way to an integrated classification, associating clinical, histological, and molecular factors.

Based on those new subtypes, innovative therapeutic approaches are already being tested actively in animal models [99] and in several ongoing clinical trials [91]. Individual treatments rely on individual molecular profiles, each of them constituting a rare event. That is why recruiting patients for prospective trials is difficult and why all specialists confronted with highly complicated cases of meningiomas should try and offer their patients’ molecular profiling, if possible as part of a clinical trial. That may allow the development of precise effective targeted therapy for patients currently in complete treatment failure.
Key issues

- With 5 cases/100,000 individuals a year, meningiomas are the most frequent primary tumor in the central nervous system. Its incidence increases with age.
- The WHO 2016 histological classification, based on the mitoses rate combined with subjective histological criteria, defines 3 grades of meningiomas, 80% being Grade I and, 15% and 2% being Grade II and III respectively.
- A wait and see strategy can often be chosen first, based on clinical and radiological observation alongside cessation of hormonal therapy (cyproterone acetate).
- Grade I meningiomas are classically cured by complete surgical resection, whereas grade II and III tumors include a continuum of more aggressive tumors that often require adjuvant treatment, either radiotherapy or stereotactic radiosurgery. Systemic treatments are not currently a first-line option.
- Basing therapeutic decisions on purely histological criteria is problematic because of the vagueness of the classification that leads to heterogeneity of so-called high grades meningiomas and high inter-observer bias. Molecular classifications, particularly DNA methylation profiles, might stratify for tumor behavior more accurately and improve the basis for decision making of additional therapy after surgery.
- New approaches combine the use of classical chemotherapy molecules (hydroxyurea, tamoxifen) and targeted treatments (anti-angiogenic molecules such as sunitinib or bevacizumab, immunotherapy, or FAK-inhibitors) depending on the molecular profile of the tumor.
- Several prospective ongoing trials include patients with recurrent or progressive meningiomas for targeted therapies.

References

Papers of special note have been highlighted as of interest (-) to readers.

21. The recent global article outlining the contribution of DNA methylation to predict meningioma prognosis. The authors find that their methylation groups stratify tumors better than current histological classification.


- Shows different patterns of evolution of atypical and anaplastic meningiomas, and gives a global indication of what could be expected in rare, aggressive cases.


64. ASTRO 2015: patients with intermediate-risk meningiomas who receive postoperative radiotherapy have a 96% 3-year progression-free survival – the ASCO post [Internet]. [cited 2017 Oct 12]. Available from: http://www.ascopost.com/News/3397.


• This article describes the bases of meningioma genetics.